Kuhn A, Gensch K, Ständer S, Bonsmann G
Hautklinik, Heinrich-Heine-Universität Düsseldorf.
Hautarzt. 2006 Apr;57(4):345-8; quiz 359. doi: 10.1007/s00105-006-1138-3.
The diagnosis of cutaneous lupus erythematosus (CLE) requires a specific diagnostic approach to identify subtypes, to address differential diagnostic considerations, and to rule out systemic organ involvement. In addition to a detailed patient's history and clinical evaluation of the skin, histopathologic and immunofluorescent examination of a skin biopsy as well as laboratory screening are recommended. Photoprovocation tests can be performed to confirm the diagnosis of CLE and to assess photosensitivity in these patients. Recently, a scoring system for the activity of the cutaneous manifestations in CLE has been developed and validated which involves anatomical areas and morphologic signs of the skin lesions. In all subtypes of CLE, antimalarials are still the treatment of choice. Advances in biotechnology have led to the development of several novel agents for the treatment of autoimmune diseases; however, controlled trials have not been performed in patients with CLE. Furthermore, there is need for specific immunointervention, especially for patients who fail to respond to standard therapies. The second part of this review will enable the reader to differentiate CLE from other diseases and to suggest specific diagnostic procedures and treatment approaches.
皮肤红斑狼疮(CLE)的诊断需要采用特定的诊断方法来识别亚型、考虑鉴别诊断因素并排除系统性器官受累情况。除了详细的患者病史和皮肤临床评估外,还建议进行皮肤活检的组织病理学和免疫荧光检查以及实验室筛查。可进行光激发试验以确诊CLE并评估这些患者的光敏性。最近,已经开发并验证了一种用于评估CLE皮肤表现活动度的评分系统,该系统涉及皮肤病变的解剖区域和形态学特征。在所有CLE亚型中,抗疟药仍然是首选治疗药物。生物技术的进步导致了几种用于治疗自身免疫性疾病的新型药物的开发;然而,尚未在CLE患者中进行对照试验。此外,需要进行特异性免疫干预,特别是对于那些对标准疗法无反应的患者。本综述的第二部分将使读者能够区分CLE与其他疾病,并提出具体的诊断程序和治疗方法。